Edgestream Partners L.P. Makes New $2.26 Million Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Edgestream Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 120,411 shares of the biotechnology company’s stock, valued at approximately $2,264,000. Edgestream Partners L.P. owned approximately 0.10% of Arrowhead Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $38,000. Van ECK Associates Corp lifted its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV lifted its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Quantbot Technologies LP acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $149,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $205,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Piper Sandler cut their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Citigroup cut their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $16.97 on Monday. The company has a market capitalization of $2.14 billion, a PE ratio of -3.28 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $16.57 and a 12 month high of $35.47. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock’s fifty day simple moving average is $19.39 and its 200 day simple moving average is $20.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,748 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This represents a 7.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66. Following the transaction, the chief executive officer now owns 3,773,802 shares of the company’s stock, valued at approximately $64,230,110.04. This trade represents a 3.41 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 280,765 shares of company stock worth $5,227,313. Corporate insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.